摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3,4-dimethyl-cyclohex-3-enylmethyl)-1H-imidazole | 317338-00-4

中文名称
——
中文别名
——
英文名称
4-(3,4-dimethyl-cyclohex-3-enylmethyl)-1H-imidazole
英文别名
5-[(3,4-dimethylcyclohex-3-en-1-yl)methyl]-1H-imidazole
4-(3,4-dimethyl-cyclohex-3-enylmethyl)-1H-imidazole化学式
CAS
317338-00-4
化学式
C12H18N2
mdl
——
分子量
190.288
InChiKey
NATSBCKHSSGXLA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    4-(3,4-dimethyl-cyclohex-3-enylmethyl)-1H-imidazole 生成 4-(3,4-dimethyl-cyclohex-3-enylmethyl)-1,3-dihydro-imidazol-2-one
    参考文献:
    名称:
    [EN] 4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS
    [FR] IMIDAZOLE-2-ONES ET IMIDAZOLE-2-THIONES 4 SUBSTITUES COMME AGONISTES DES ADRENO-RECEPTEURS ALPHA-2B ET ALPHA-2C
    摘要:
    式(I)的化合物:其中X为S,变量的含义如规范中定义的那样,对alpha2B和/或alpha2C肾上腺素受体具有特异性或选择性,优先于alpha2A肾上腺素受体,并且因此具有无或仅有极小的心血管和/或镇静活性。这些式(I)的化合物在哺乳动物,包括人类中,作为药物用于治疗对alpha2B肾上腺素受体激动剂治疗有响应的疾病和/或缓解症状是有用的。式(I)的化合物,其中X为O,还具有有利的特性,即它们具有无或仅有极小的心血管和/或镇静活性,并且适用于治疗无或仅有极小的心血管和/或镇静活性的疼痛和其他症状。
    公开号:
    WO2003099795A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    [EN] 4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS
    [FR] IMIDAZOLE-2-ONES ET IMIDAZOLE-2-THIONES 4 SUBSTITUES COMME AGONISTES DES ADRENO-RECEPTEURS ALPHA-2B ET ALPHA-2C
    摘要:
    式(I)的化合物:其中X为S,变量的含义如规范中定义的那样,对alpha2B和/或alpha2C肾上腺素受体具有特异性或选择性,优先于alpha2A肾上腺素受体,并且因此具有无或仅有极小的心血管和/或镇静活性。这些式(I)的化合物在哺乳动物,包括人类中,作为药物用于治疗对alpha2B肾上腺素受体激动剂治疗有响应的疾病和/或缓解症状是有用的。式(I)的化合物,其中X为O,还具有有利的特性,即它们具有无或仅有极小的心血管和/或镇静活性,并且适用于治疗无或仅有极小的心血管和/或镇静活性的疼痛和其他症状。
    公开号:
    WO2003099795A1
点击查看最新优质反应信息

文献信息

  • IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS
    申请人:ALLERGAN, INC.
    公开号:EP1370533B1
    公开(公告)日:2015-05-06
  • ALPHA-2B RECEPTOR AGONIST AND 5HT4 SEROTONIN RECEPTOR COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS
    申请人:Brooks Gregory F.
    公开号:US20080153825A1
    公开(公告)日:2008-06-26
    Disclosed herein is a pharmaceutical composition comprising a 5-HT4 serotonin receptor agonist and an alpha-2B receptor agonist. The composition is effective for treating gastrointestinal motility disorders, and methods of treating such disorders using the composition and compounds comprising it are also disclosed.
  • ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN
    申请人:Gil Daniel W.
    公开号:US20080153874A1
    公开(公告)日:2008-06-26
    Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an alpha-2B receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composition and the compounds comprising it are also disclosed.
  • ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS
    申请人:Brooks Gregory F.
    公开号:US20080153881A1
    公开(公告)日:2008-06-26
    Disclosed herein is a pharmaceutical composition comprising an acid reducer and an alpha-2B receptor agonist. The composition is effective for treating gastrointestinal motility disorders, and methods of treating such disorders using the composition and compounds comprising it are also disclosed.
  • ALPHA-2B RECEPTOR AGONIST AND RELAXANT COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS
    申请人:Brooks Gregory F.
    公开号:US20080153927A1
    公开(公告)日:2008-06-26
    Disclosed herein is a pharmaceutical composition comprising a relaxant and an alpha-2B receptor agonist. The composition is effective for treating gastrointestinal motility disorders, and methods of treating such disorders using the composition and compounds comprising it are also disclosed.
查看更多